|
|
|
|
|
|
|
10.08.26 - 08:39
|
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer (Business Wire)
|
|
|
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome
Markus Jensen appointed Chief Medical Officer, bringing leadership continuity to execute TELLOMAK-3 and to prepare for upcoming IPH4502 development milestones
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding Sonia Quaratino.
The planned initiation of the TELLOMAK-3 confirmatory Phase 3 study marks an important step for Innate as the Company enters a new phase of late-stage clinical an...
|
|
|
|
|
08.06.26 - 16:57
|
XETR: Deletion of Instruments from XETRA - 08.06.2026 (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 08.06.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 08.06.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US0311001004 AMETEK Inc.
US1713401024 Church & Dwight Co. Inc.
US1729081059 Cintas Corp.
US22052L1044 Corteva Inc.
US2310211063 Cummins Inc.
US2533931026 Dicks Sporting Goods Inc.
US2910111044 Emerson Electric Co.
US30212P3038 Expedia Group Inc.
FR0004163111 Genfit S.A.
US37940X1028 Global Payments Inc.
US43300A2033 Hilton Worldwide Holdings Inc.
US45168D1046 IDEXX Laboratories Inc.
FR0010331421 Innate Pharma S.A.
US46266C1053 IQVIA Holdings Inc.
US5380341090 Live Nation Entertainment Inc.
US5719032022 Marriott International Inc.
US57667L1070 Match Group Inc.
US5926881054 Mettler-Toledo International Inc.
US5950171042 Microchip Technology Inc.
US6200763075 Motorola Solutions Inc.
US6819191064 Omnicom Group Inc.
US68902V1070 Otis Worldwi...
|
|
|
22.05.26 - 07:03
|
Outcome of Innate Pharma′s 2026 Annual General Meeting (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 21, 2026, in Marseille. All resolutions were voted.
A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.
The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026 section of the Company's website.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.
Innate Pharma is advancing a portfolio of differ...
|
|
|
|
|
|
|
|
|
13.05.26 - 07:06
|
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results (Business Wire)
|
|
|
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures
IPH4502 (Nectin-4 ADC) continues to show preliminary anti-tumor activity with favorable safety profile to date; the maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion
PACIFIC-9 Phase 3 trial, which includes monalizumab and is led by AstraZeneca, continues to advance toward a planned H2 2026 data readout
IPH5201 (anti-CD39 antibody), developed in collaboration with AstraZeneca, showed encouraging early results presented in a Clinical Trials Plenary Session at AACR 2026, supporting continued investigation in the MATISSE Phase 2 study in non-small cell lung cancer (NSCLC)
Cash position of €25.4 million1 as of March 31, 2026, with an anticipated cash runway until the end of Q3 2026
Con...
|
|
|
06.05.26 - 07:03
|
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--$Innate #Biotech--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to provide an update on business progress for the first quarter of 2026.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication & Commercial strategy
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/211092666
Participants may also join via telephone using the following registration link: https://events.q4inc.com/analyst/211092666?pwd=nO162IiF
This information is also available on the ...
|
|
|
17.04.26 - 17:12
|
XETR: Deletion of Instruments from XETRA - 17.04.2026 -1- (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 17.04.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US02043Q1076 Alnylam Pharmaceuticals Inc.
US0255371017 American Electric Power Co. Inc.
US0311001004 AMETEK Inc.
US0530151036 Automatic Data Processing Inc.
GB00BPQY8M80 Aviva PLC
IE00BD1RP616 Bank of Ireland Group PLC
US14448C1045 Carrier Global Corp.
US8085131055 Charles Schwab Corp.
US16119P1084 Charter Communications Inc. [Del.]
US1713401024 Church & Dwight Co. Inc.
US1255231003 Cigna Group, The
US1729081059 Cintas Corp.
US12572Q1058 CME Group Inc.
US1924461023 Cognizant Technology Solutions Corp.
US2091151041 Consolidated Edison Inc.
US22052L1044 Corteva Inc.
US1264081035 CSX Corp.
US2310211063 Cummins Inc.
US2435371073 Deckers Outdoor Corp.
DK0060738599 Demant AS
US2533931026 Dics Sporting Goods Inc.
US2566771059 Dollar General Co...
|
|
|
13.04.26 - 07:03
|
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#Actionnaires--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 21, 2026, at its headquarters, 117 avenue de Luminy, 13009 Marseille.
The notice of meeting for this AGM was published on April 13, 2026 in the French Bulletin des annonces légales obligatoires (BALO). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.
Documents and information relating to the AGM will be made available to shareholders in compliance with current regulations on the Investors section of the Company's website.
The AGM will also be broadcast live and accessible at the following link: Innate Pharma 2026 Annual General Meeting
A guided tour of the Company's laboratories will be organized on the same day at 9:15 a.m. CEST for shareholders. Shareholders can register for the tour via the follo...
|
|
|
02.04.26 - 10:03
|
Innate Pharma Files Its 2025 Universal Registration Document (Document D′enregistrement Universel) and 2025 Form 20-f Annual Report (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2025 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2025 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 1st, 2026. It can be downloaded (in French) on the Company's website and on the AMF's website.
The following documents are incorporated into the Universal Registration Document:
the annual financial report,
the annual management report,
the corporate governance report provided for under Article L. 225-37 of the French Commercial Code,
the report of Statutory Auditors.
The Company also announced today the filing of its Form 20-F annual report for the year ending December 31, 2025 with the United States Securities and Exchange Commission (“SEC”) on April 1st, 2026. It can be also be accessed on the Company's website and on ...
|
|
|
|
|
|
|
26.03.26 - 07:06
|
Innate Pharma Reports Full Year 2025 Financial Results and Business Update (Business Wire)
|
|
|
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures
IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels
Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout
IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for an oral presentation in one of the Clinical Trials Plenary Session Sessions at the AACR Annual Meeting 2026, on April 21
Cash position of €44.8 million1 as of December 31, 2025 with an anticipated cash runway until the end of Q3 2026
Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT
MARSEILLE, France--(BUSINESS WIRE...
|
|
|
19.03.26 - 07:06
|
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#Biotech--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2025.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication and Commercial Strategy
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/704730270
Participants may also join via telephone using the following registration link: https://events.q4inc.com/analyst/704730270?pwd=usHLLD39
This information can...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
